Evidence-Based Practice: Temozolomide Beyond Glioblastoma
Purpose of Review
Temozolomide is a first-line treatment for newly diagnosed glioblastoma. In this review, we will examine the use of temozolomide in other contexts for treating gliomas, including recurrent glioblastoma, glioblastoma in the elderly, diffuse low- and high-grade gliomas, non-diffuse gliomas, diffuse intrinsic pontine glioma (DIPG), ependymoma, pilocytic astrocytoma, and pleomorphic xanthoastrocytoma.
Temozolomide improved survival in older patients with glioblastoma, anaplastic gliomas regardless of 1p/19q deletion status, and progressive ependymomas. Temozolomide afforded less toxicity and comparable efficacy to radiation in high-risk low-grade gliomas and to platinum-based chemotherapy in pediatric high-grade gliomas.
The success of temozolomide in promoting survival has expanded beyond glioblastoma to benefit patients with non-glioblastoma tumors. Identifying practical biomarkers for predicting temozolomide susceptibility, and establishing complementary agents for chemosensitizing tumors to temozolomide, will be key next steps for future success.
KeywordsTemozolomide Low grade glioma GBM in the elderly Ependymoma Pilocytic astrocytoma Pleomorphic xanthoastrocytoma DIPG Bevacizumab
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 1.• Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J med. 2005;352:987–96. https://doi.org/10.1056/NEJMoa043330 This study demonstrated, both clinically and statistically, significant survival benefit with the addition of temozolomide to radiotherapy for glioblastoma, without significant toxicity. This has now become the standard of care following maximal safe surgical resection.CrossRefPubMedGoogle Scholar
- 2.Hart MG, Garside R, Rogers G, Stein K, Grant R. Temozolomide for high grade glioma. Cochrane Database Syst Rev. 2013:Cd007415. https://doi.org/10.1002/14651858.CD007415.pub2.
- 7.Brandes AA, Tosoni A, Cavallo G, Bertorelle R, Gioia V, Franceschi E, et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer. 2006;95:1155–60. https://doi.org/10.1038/sj.bjc.6603376.CrossRefPubMedPubMedCentralGoogle Scholar
- 14.• Weller M, Tabatabai G, Kastner B, Felsberg J, Steinbach JP, Wick A, et al. MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial. Clin Cancer Res. 2015;21:2057–64. https://doi.org/10.1158/1078-0432.Ccr-14-2737 This study aimed to identify how dose-intense regimens of temozolomide may be beneficial in treatment of recurrent glioblastoma. There was no major difference in efficacy between one week on/one week off temozolomide compared with three weeks on/one week off. It did, however, indicate that temozolomide rechallenge should not be considered for patients with an unmethylated MGMT promoter status, although it is a viable option for methylated-MGMT tumors, as the median time to treatment failure, progression-free survival, and overall survival were longer versus unmethylated tumors.CrossRefPubMedGoogle Scholar
- 19.Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13:916–26. https://doi.org/10.1016/s1470-2045(12)70265-6.CrossRefPubMedGoogle Scholar
- 20.Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13:707–15. https://doi.org/10.1016/s1470-2045(12)70164-x.CrossRefPubMedGoogle Scholar
- 21.Gallego Perez-Larraya J, Ducray F, Chinot O, Catry-Thomas I, Taillandier L, Guillamo JS, et al. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. J Clin Oncol. 2011;29:3050–5. https://doi.org/10.1200/jco.2011.34.8086.CrossRefPubMedGoogle Scholar
- 22.• Perry JR, Laperriere N, O'Callaghan CJ, Brandes AA, Menten J, Phillips C, et al. Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. N Engl J Med. 2017;376:1027–37. https://doi.org/10.1056/NEJMoa1611977 Since previous trials implementing Stupp protocol largely excluded patients > 70 years of age, there were few data about the benefit of temozolomide for older patients with glioblastoma. This study was notable for showing that addition of temozolomide does provide survival benefit in elderly patients, even if overall prognosis is poorer compared to younger patients.CrossRefPubMedGoogle Scholar
- 23.Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016(131):803–20. https://doi.org/10.1007/s00401-016-1545-1.
- 26.Lecavalier-Barsoum M, Quon H, Abdulkarim B. Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. Cochrane Database Syst Rev. 2014:Cd007104. https://doi.org/10.1002/14651858.CD007104.pub2.
- 28.Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Butowski N, Fenstermaker RA, Forsyth P, Hattangadi-Gluth J, Holdhoff M, Howard S, Junck L, Kaley T, Kumthekar P, Loeffler JS, Moots PL, Mrugala MM, Nagpal S, Pandey M, Parney I, Peters K, Puduvalli VK, Ragsdale J 3rd, Rockhill J, Rogers L, Rusthoven C, Shonka N, Shrieve DC, Sills AK Jr, Swinnen LJ, Tsien C, Weiss S, Wen PY, Willmarth N, Bergman MA, Engh A. NCCN Clinical Practice Guidelines in Oncology. Central Nervous System Cancers (Version I.2018). Accessed November 1, 2018.Google Scholar
- 30.• Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033–26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016;17:1521–32. https://doi.org/10.1016/s1470-2045(16)30313-8 This was the first study to randomly assign patients with low-grade glioma and at least one high-risk feature to radiotherapy alone or temozolomide chemotherapy alone. Although there was no improvement in progression-free survival with chemotherapy alone, temozolomide may prevent or delay patients from the side effects of radiation by using a similarly effective therapy. Subgroup analysis suggested that IDH mutant, non-co-deleted tumors treated with radiotherapy had a longer progression-free survival than those treated with temozolomide (such that temozolomide treatment alone might be deleterious).CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Fisher BJ, Hu C, Macdonald DR, Lesser GJ, Coons SW, Brachman DG, et al. Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of radiation therapy oncology group 0424. Int J Radiat Oncol Biol Phys. 2015;91:497–504. https://doi.org/10.1016/j.ijrobp.2014.11.012.CrossRefPubMedPubMedCentralGoogle Scholar
- 32.Fisher B, Zhang P, Macdonald D, Chakravarti A, Lesser G, Fox S, et al. ACTR-2. NRG Oncology/RTOG 0424: Long term results of a phase II study of temozolomide-based chemoradiotherapy regimen for high risk low-grade gliomas. Neuro-Oncology. 2018;20. https://doi.org/10.1093/neuonc/noy148.039.
- 33.• Bell EH, Zhang P, Fisher BJ, Macdonald DR, McElroy JP, Lesser GJ, et al. Association of MGMT promoter methylation status with survival outcomes in patients with high-risk glioma treated with radiotherapy and temozolomide: an analysis from the NRG oncology/RTOG 0424 trial. JAMA Oncol. 2018;4:1405–9. https://doi.org/10.1001/jamaoncol.2018.1977 This was the first study to demonstrate MGMT methylation as an independent prognostic factor in low-grade glioma treated with temozolomide and radiotherapy.CrossRefPubMedGoogle Scholar
- 34.Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009;27:5874–80. https://doi.org/10.1200/jco.2009.23.6497.CrossRefPubMedGoogle Scholar
- 35.• Izquierdo C, Alentorn A, Idbaih A, Simo M, Kaloshi G, Ricard D, et al. Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics. J Neurooncol. 2018;136:533–9. https://doi.org/10.1007/s11060-017-2677-4 This group examined the growth kinetics of co-deleted low-grade gliomas who were treated with upfront temozolomide, finding that most tumors resumed their growth within 3 years of treatment. They argued that volumetric analysis to identify early tumor progression can prevent unnecessary exposure to temozolomide, which could put patients at risk for malignant progression (based on mutational analyses proposed that TMZ exposure can lead to acquisition of a hypermutation, leading to progression). CrossRefPubMedGoogle Scholar
- 36.• van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet. 2017;390:1645–53. https://doi.org/10.1016/s0140-6736(17)31442-3 Before this trial, there had not been a well-designed study supporting adjuvant temozolomide for grade II and III gliomas. This study demonstrated that the less-chemosensitive 1p/19q non-co-deleted anaplastic gliomas still derived benefit from temozolomide therapy. It showed prolonged overall survival with 12 cycles of adjuvant temozolomide in addition to radiotherapy. The role of concurrent temozolomide therapy is not yet established. CrossRefPubMedPubMedCentralGoogle Scholar
- 38.van Zanten SEM V, Lane A, Heymans MW, Baugh J, Chaney B, Hoffman LM, et al. External validation of the diffuse intrinsic pontine glioma survival prediction model: a collaborative report from the international DIPG registry and the SIOPE DIPG registry. J Neurooncol. 2017;134:231–40. https://doi.org/10.1007/s11060-017-2514-9.CrossRefGoogle Scholar
- 41.Bailey S, Howman A, Wheatley K, Wherton D, Boota N, Pizer B, et al. Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy—results of a United Kingdom phase II trial (CNS 2007 04). Eur J Cancer. 2013;49:3856–62. https://doi.org/10.1016/j.ejca.2013.08.006.CrossRefPubMedPubMedCentralGoogle Scholar
- 42.Cohen KJ, Heideman RL, Zhou T, Holmes EJ, Lavey RS, Bouffet E, et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the children's oncology group. Neuro-Oncology. 2011;13:410–6. https://doi.org/10.1093/neuonc/noq205.CrossRefPubMedPubMedCentralGoogle Scholar
- 43.Sirachainan N, Pakakasama S, Visudithbhan A, Chiamchanya S, Tuntiyatorn L, Dhanachai M, et al. Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and cis-retinoic acid in children with diffuse intrinsic pontine glioma. Neuro-Oncology. 2008;10:577–82. https://doi.org/10.1215/15228517-2008-025.CrossRefPubMedPubMedCentralGoogle Scholar
- 45.• Seidel C, von Bueren AO, Bojko S, Hoffmann M, Pietsch T, Gielen GH, et al. Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen: acute toxicity in pediatric high-grade glioma patients. Strahlenther Onkol. 2018:194:215–224. Doi: https://doi.org/10.1007/s00066-017-1218-6. This study identified that cisplatin-based chemotherapy demonstrated increased toxicity (mostly hematologic), with more interruptions of treatment, in comparison with temozolomide in pediatric high-grade gliomas. While the efficacy of chemotherapies for pediatric high-grade glioma are similar (and poor), the authors argued for temozolomide use with radiotherapy because of relatively lower toxicity.
- 46.• Flannery PC, JA DS, Amani V, Venkataraman S, Lemma RT, Prince EW, et al. Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma. Oncol Rep. 2018;39:455–64. https://doi.org/10.3892/or.2017.6122 AZD2014 is a MTOR complex 1 and 2 inhibitor that was studied in three patient-derived DIPG cell lines. Its use potentiated greatly increased antitumor efficacy, via increased inhibition of cell self-renewal. It also demonstrated a synergistic relationship with dose-dependent radiotherapy, and also with other chemotherapies.CrossRefPubMedGoogle Scholar
- 56.• Ruda R, Bosa C, Magistrello M, Franchino F, Pellerino A, Fiano V, et al. Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study. Neuro Oncol. 2016;18:261–8. https://doi.org/10.1093/neuonc/nov167 Before this study, there were few data to guide the addition of further chemotherapy to recurrent or progressive ependymomas despite initial resection and radiation. Although the efficacy of temozolomide among these select patients was variable, favorable results in chemotherapy-naïve patients suggested a role for temozolomide after failure of first-line treatments. Intriguingly, these benefits occurred independent of MGMT methylation status.CrossRefPubMedGoogle Scholar
- 57.Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol. 2014;16(Suppl 4):iv1–63. https://doi.org/10.1093/neuonc/nou223.CrossRefPubMedPubMedCentralGoogle Scholar
- 65.Zhu M, Zhang C, Zhao K, Wang L, Sun J, Feng Y, et al. Anaplastic pleomorphic xanthoastrocytoma with disseminated growth pattern at the time of diagnosis as well as after treatment: case report and review of literature. Chinese Neurosurgical Journal. 2017;3:22. https://doi.org/10.1186/s41016-017-0087-2.CrossRefGoogle Scholar
- 66.Thompson EM, Landi D, Ashley D, Keir ST, Bigner D. Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status. J Neuro-Oncol. 2018;140:261–8. https://doi.org/10.1007/s11060-018-2975-5.CrossRefGoogle Scholar
- 67.Precision Medicine in Cancer Treatment. https://www.cancer.gov/about-cancer/treatment/types/precision-medicine. Accessed November 1, 2018.
- 68.Kaley T, Touat M, Subbiah V, Hollebecque A, Rodon J, Lockhart AC, et al. BRAF inhibition in BRAF(V600)-mutant gliomas: results From the VE-BASKET study. J Clin Oncol. 2018;Jco2018789990. https://doi.org/10.1200/jco.2018.78.9990.